Table 1.
Quantitative analysis of BrdU immunoreactive cells and their phenotypes in subregions of the dentate gyrus after BrdU labeling1-a
| Time after ischemia | Treatment | Subregions of the dentate gyrus | |||||
|---|---|---|---|---|---|---|---|
| GCL + SGZ | Dentate hilus | ||||||
| Total1-b | NeuN1-c | GFAP1-c | Total | NeuN | GFAP | ||
| 15 d | Control | 45 ± 5 | 0 | 0 | 2 ± 1 | 0 | 0 |
| Ischemia | 220 ± 57 | 0 | 0 | 17 ± 6 | 0 | 2 ± 1 | |
| 26 d | Control | 16 ± 3 | 3 ± 1 | 0 | 3 ± 1 | 0 | 0 |
| Ischemia | 113 ± 23 | 30 ± 5 | 0 | 69 ± 37 | 0 | 7 ± 3.2 | |
| 40 d | Control | 11 ± 3 | 8 ± 2 | 0 | 3 ± 1 | 0 | 0 |
| Ischemia | 91 ± 6 | 56 ± 4 | 0 | 78 ± 41 | 0 | 20 ± 6 | |
F1-a
Ischemic and control animals received a series of BrdU injections (50 mg/kg, i.p., twice daily) 9–12 d after surgery.
F1-b
BrdU immunoreactive nuclei labeled by FITC detected by immunofluorescence microscopy (n = 6 per group).
F1-c
BrdU-labeled cells also immunoreactive for NeuN or GFAP, as detected by confocal microscopy (see Materials and Methods).